We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Automated Diagnostic Immunoassay Testing Made Effortless

By LabMedica International staff writers
Posted on 25 Nov 2010
A fully automated system for processing immunoassays is rapid, straightforward, more cost-effective and less labor intensive. More...


Project 24, quickly and easily processes 96-well microplates for total assay optimization. Project 24 is currently in the final stages of development, but not yet available for customer orders.

The New Dynex clinical diagnostics processing system for fully automated enzyme linked immunoassays (ELISA) testing is manufactured by Magellan Biosciences, (Chelmsford, MA, USA). A preview of the system was shown at MEDICA 2010 trade fair being held in Düsseldorf, Germany from November 17-20, 2010.

The manufacturers claim that the new system is a revolutionary approach to assay kit packaging. Rather than the manual reagent loading and data input of current systems, they have vastly simplified the process working with assay manufacturers to develop preloaded kits that the user adds directly from the box. The direct-load kit format eliminates the need for manual reagent transfer and includes a barcode system that electronically communicates all the information needed for a successful run. This eliminates manual data entry of kit-specific data, minimizes errors, and tracks all kit, sample, and consumable inventory so users are assured that when they walk away, the system will complete its work list fully.

Hiroshi Uchida, PhD, president and CEO of the company added, "Project 24 optimizes microplate ELISA testing by bringing true automation and extraordinary ease-of-use to what historically has been a tedious and time-consuming process. We have removed all of the manual set-up and data entry from the workflow, eliminating nearly 50 % of the hands-on time compared with traditional systems, significantly reducing cost of ownership as well as cost per test. Additionally, the Project 24 provides Magellan with a powerful platform for future development, including multiplexed immunoassay and molecular testing."

Related Links:

Magellan Biosciences




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.